Friedrich Scheiflinger

Baxalta Innovations GmbH, Donau City Str. 7
Vienna, 1220, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII.

Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII.

Journal: Molecular therapy. Methods & clinical development

Published: August 30, 2024

Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease.

Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 10, 2022

Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.

Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.

Journal: Haematologica

Published: October 26, 2021

Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey.

Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey.

Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis

Published: July 16, 2021

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.

Journal: Molecular therapy. Methods & clinical development

Published: August 18, 2020

A bispecific antibody demonstrates limited measurability in routine coagulation assays.

A bispecific antibody demonstrates limited measurability in routine coagulation assays.

Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis

Published: May 30, 2020

Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release.

Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release.

Journal: Molecular therapy. Methods & clinical development

Published: February 19, 2020

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.

Journal: Blood

Published: December 23, 2019

Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and Pharmacokinetics.

Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and Pharmacokinetics.

Journal: Antibodies (Basel, Switzerland)

Published: July 23, 2019

Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors.

Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 19, 2019

Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.

Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.

Journal: The Journal of pharmacology and experimental therapeutics

Published: May 21, 2019

Identification of cysteine thiol-based linkages in ADAMTS13 in support of a non-proteolytic regulation of von Willebrand factor.

Identification of cysteine thiol-based linkages in ADAMTS13 in support of a non-proteolytic regulation of von Willebrand factor.

Journal: Journal of thrombosis and haemostasis : JTH

Published: March 26, 2019

Showing 1-12 of 67

Last Updated: 09/26/2026